Stomach bleeding prevention for stroke patients on blood thinners
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new medicine called zastaprazan, which helps reduce stomach acid, to see if it can prevent bleeding in the stomach and intestines for people who are on blood thinners after a stroke. If you are taking blood thinners, this medicine might lower your risk of serious stomach bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old.
- You have had a mini-stroke or a stroke in the past 6 months.
- You are starting or currently taking blood-thinning medications (like aspirin with another antiplatelet, or an anticoagulant) for at least 3 weeks.
- You have not had a stomach ulcer or bleeding in the past year.
- You do not have severe liver disease, advanced kidney failure, or a history of broken bones due to osteoporosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a stomach-protecting medicine called tegoprazan for people who have had a stroke and are starting antiplatelet therapy. It aims to prevent stomach complications like ulcers or bleeding.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This trial tests if a newer acid-reducing drug is better than standard care for preventing stomach problems in people who recently had a heart attack and a stent placed. It could help those who need stomach protection while on blood thinners.
This trial compares a potassium-competitive acid blocker to a proton pump inhibitor to help prevent stomach or intestinal bleeding in people at high risk who take blood-thinning medicines. It may help reduce dangerous GI bleeding while you stay on heart/stroke medicines.
This trial tests if a new stomach acid medicine (Zastaprazan) affects how well clopidogrel works in heart patients who have had a stent placed. It aims to help people who need both clopidogrel and a stomach acid drug after a procedure.
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.